Ocular side effects of anti-tubercular drugs in patients receiving Anti-Tb treatment at tertiary care center

---

Original Article

Author Details : Trupti M Solu, Kruti Panchal*

Volume : 6, Issue : 3, Year : 2020

Article Page : 187-191

https://doi.org/10.18231/j.ijooo.2020.042

Suggest article by email

Get Permission

---

Abstract

Introduction: India is among the countries that carry the highest burden for tuberculosis. Antitubercular drugs are frequently associated with ocular toxicity. Among ATT, ethambutol is the most commonly implicated drug causing optic neuropathy. For assessing spectrum of ATT induced ocular toxicity, clinical presentation, monitoring, and preventive measures a prospective observational follow up study was conducted.
Materials and Methods: A newly diagnosed drug susceptible pulmonary tuberculosis patients referred to ophthalmology OPD during a study period from May 2018 - October 2019 at a tertiary care hospital. The detailed history, best corrected visual acuity, fundus examination, color vision test and visual fields were carried out in all patients at the start of treatment and thereafter every month up to 6 months after initiation of ATT.
Results: During six month follow up study, out of 94 study participants, 14 eyes of seven patients (7.44%) had drop in visual acuity from baseline (p value = 0.03). Total 10 eyes of five patients (5.32%) had developed colour vision abnormality (p=0.001) and 8 eyes of four patients had developed optic disc changes from baseline. Visual field defects were noted in ten (5.32%) eyes (p = 0.001). In our study ATT related ocular toxicity was found in 5.32% on standard HRZE drug regimen.
Conclusion: The course of ethambutol-induced ocular toxicity is unpredictable. The early recognition of ocular toxicity is paramount to prevent irreversible visual loss.

Keywords: Tuberculosis, Ethambutol, Optic neuropathy, Visual field defects, Colour vision.

How to cite : Solu T M, Panchal K , Ocular side effects of anti-tubercular drugs in patients receiving Anti-Tb treatment at tertiary care center. IP Int J Ocul Oncol Oculoplasty 2020;6(3):187-191

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.